Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | RARG | P13631 | 5/20 | 0.36 |
| ▸ | RARA | P10276 | 4/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.35 |
| ▸ | NR0B2 | Q15466 | 2/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5828810 | 0.90 | RARB (0.44) | RARBHDAC11HDAC7HDAC8HDAC6 | |
| SCHEMBL6449246 | 0.85 | ALDH1A1 (0.35) | RARBHDAC11HDAC7HDAC8HDAC6 | |
| SCHEMBL6543153 | 0.85 | RARB (0.40) | RARBHDAC11HDAC7HDAC8HDAC6 | |
| SCHEMBL6543150 | 0.85 | RARB (0.40) | RARBHDAC11HDAC7HDAC8HDAC6 | |
| SCHEMBL405279 | 0.84 | RARB (0.64) | RARBHDAC11HDAC7HDAC8HDAC6 | |
| SCHEMBL405278 | 0.84 | RARB (0.64) | RARBHDAC11HDAC7HDAC8HDAC6 | |
| SCHEMBL6620633 | 0.84 | RARB (0.31) | RARBALDH1A1HSD17B10TDP1 | |
| SCHEMBL5828590 | 0.82 | PTPN11 (0.54) | TDP1PTPN11DYRK3CLK1CLK2 | |
| SCHEMBL5828587 | 0.82 | PTPN11 (0.54) | TDP1PTPN11DYRK3CLK1CLK2 | |
| SCHEMBL403676 | 0.81 | HDAC11 (0.54) | RARBHDAC11HDAC7HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100330200-A1 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-30 | — | — | US | claimed |
| EP-2101820-A2 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-09-23 | — | — | EP | claimed |
| WO-2008077772-A2 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2008-07-03 | — | — | WO | claimed |
| US-8101793-B2 | Anticarcinogenic and antimetastasis agents; leukemia or Hodgkin's disease. | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-01-24 | — | — | US | disclosed |
| US-8101793-B2 | Anticarcinogenic and antimetastasis agents; leukemia or Hodgkin's disease. | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-01-24 | — | — | US | disclosed |
| US-8101793-B2 | Anticarcinogenic and antimetastasis agents; leukemia or Hodgkin's disease. | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-01-24 | — | — | US | disclosed |
| US-20100330200-A1 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-30 | — | — | US | disclosed |
| EP-1412317-B1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMOR AND PROAPOPTOTIC ACTIVITIES | SIGMA TAU IND FARMACEUTI (IT) | 2010-12-22 | — | — | EP | disclosed |
| EP-1412317-B1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMOR AND PROAPOPTOTIC ACTIVITIES | SIGMA TAU IND FARMACEUTI (IT) | 2010-12-22 | — | — | EP | disclosed |
| EP-2101820-A2 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-09-23 | — | — | EP | disclosed |
| US-7449495-B2 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-11-11 | — | — | US | disclosed |
| US-20040235757-A1 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-11-25 | — | — | US | disclosed |
| EP-1421061-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | Incyte San Diego Incorporated (US) | 2004-05-26 | — | — | EP | disclosed |
| EP-1412317-A1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMOR AND PROAPOPTOTIC ACTIVITIES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-04-28 | — | — | EP | disclosed |
| EP-1385465-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | Incyte San Diego, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003016267-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INCORPORATED (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003011808-A1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMORAL AND PROAPOPTOTIC ACTIVITIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-02-13 | — | — | WO | disclosed |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE GENOMICS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002072009-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | MAXIA PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | RARB 1344/4885HDAC11 1128/4885HDAC7 1221/4885 |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | CCNY, HRAS, AHR | RARB 1465/4885HDAC11 48/4885HDAC7 249/4885 |
| US-20040235757-A1 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | RARA, RARB, RARG | RARB 2/4885HDAC11 883/4885HDAC7 1007/4885 |
| US-20100330200-A1 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | CXCR4, RARA, CXCL12 | RARB 4/4885HDAC11 1919/4885HDAC7 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.